dc.creatorFernandez, Ariel
dc.date.accessioned2022-02-01T18:57:56Z
dc.date.accessioned2022-10-15T01:06:36Z
dc.date.available2022-02-01T18:57:56Z
dc.date.available2022-10-15T01:06:36Z
dc.date.created2022-02-01T18:57:56Z
dc.date.issued2019-06
dc.identifierFernandez, Ariel; Protein structural defects enable pharmaceutical targeting while functionalizing the M2 proton channel; Academic Press Inc Elsevier Science; Biochemical and Biophysical Research Communications; 514; 1; 6-2019; 86-91
dc.identifier0006-291X
dc.identifierhttp://hdl.handle.net/11336/151094
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4328154
dc.description.abstractThe influenza M2 (22–46) proton channel is therapeutically targetable and a prototype for proton transport across membranes. Conduction initiation, requiring a hydronium formed with exceptionally high pKa, remains nebulous. We tackle the problem by focusing on the dynamic interplay between protein structure and solvent interface. We identify two packing defects in the protein subunits that predict exactly the low and high-affinity drug-binding sites. The latter defect frustrates water coordination, enhancing water basicity and stabilizing the nearby hydronium that forms upon proton penetration in the channel. Thus, the trigger of proton conduction is directly related to the high-affinity binding site. The findings, in quantitative agreement with affinity measurements, are consistent with the targetable functional nature of protein packing defects. These findings enable the design of proton-conducting biomimetic materials, where the epistructure may be engineered to tune the basicity of interfacial water.
dc.languageeng
dc.publisherAcademic Press Inc Elsevier Science
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.bbrc.2019.04.094
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/abs/pii/S0006291X19307363
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectHYDROGEN BOND
dc.subjectINFLUENZA VIRUS
dc.subjectPROTON CHANNEL
dc.subjectSTRUCTURAL BIOLOGY
dc.subjectTRANSMEMBRANE DOMAIN
dc.subjectWATER FRUSTRATION
dc.titleProtein structural defects enable pharmaceutical targeting while functionalizing the M2 proton channel
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución